FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207194677> ?p ?o ?g. }

• W3207194677 endingPage "S903" @default.
• W3207194677 startingPage "S903" @default.
• W3207194677 abstract "The recommended treatment for patients with unresectable stage 3 NSCLC is definitive chemoradiation followed by 1 year of maintenance durvalumab. The objective of our study was to assess the use of maintenance durvalumab based on patient and physician characteristics among stage 3 NSCLC patients in the U.S. Analyses were conducted in both open claims (IQVIA pharmacy and medical claims data) and adjudicated closed claims (IQVIA PharMetrics Plus Health Plan Claims Database). Patients were filtered with the following criteria: (1) ≥1 lung cancer diagnosis code Nov 2017 – Nov 2020, (2) retain any metastatic/advanced codes, (3) exclude SCLC patients, and (4) limit to single primary tumor looking back to Nov 2015. Lastly, patients must have been ≥18 years, have no lung cancer surgery codes during the observation period, and received chemoradiation after the index date and prior to May 31, 2020. Logistic regression was used to evaluate differences between patients who received durvalumab following chemoradiation compared to those who did not. 8071 NSCLC patients were included from the open claims source; 1794 (22.2%) received maintenance durvalumab (Table 1). Overall, distributions of baseline characteristics were similar between durvalumab and non-durvalumab patients. Durvalumab patients had a higher probability of older age (≥65 years) (odds ratio [OR] 1.2, 95% CI 1.1 – 1.3) and being treated in the Midwest (OR 1.2, 95% CI 1.0 – 1.4), respectively. Among non-durvalumab users (N=6277), chemotherapy (n=2785; 44.4%) and pembrolizumab (n=2047; 32.6%) were most commonly used, with combination chemotherapy treatment given to n=1629 (26.0%) patients. 357 NSCLC patients were included from the closed claims source; 127 (35.6%) received maintenance durvalumab (Table 1b). Overall, distributions of baseline characteristics were similar between durvalumab and non-durvalumab patients. None of the baseline characteristics differed between exposure groups (all 95% CIs crossed the null). Among non-durvalumab users (N=230), chemotherapy (n=124; 53.9%) and pembrolizumab (n=82; 35.6%) were most commonly used, with combination chemotherapy treatment given to n=63 (27.4%) patients. The rate of durvalumab utilization was overall low in both the open and closed claims data sources (22.2% and 35.6% respectively). In the open claims data source, durvalumab utilization was higher for patients ≥65 years and treated in the Midwest; similar trends were observed in the closed claims database but did not reach significance. Interesting findings include a higher rate of pembrolizumab utilization than expected. Future studies are needed to better understand these current practice patterns in the U.S." @default.
• W3207194677 created "2021-10-25" @default.
• W3207194677 creator A5018209224 @default.
• W3207194677 creator A5018712784 @default.
• W3207194677 creator A5025327083 @default.
• W3207194677 creator A5063005747 @default.
• W3207194677 creator A5068203031 @default.
• W3207194677 creator A5078183404 @default.
• W3207194677 creator A5089989046 @default.
• W3207194677 date "2021-10-01" @default.
• W3207194677 modified "2023-10-14" @default.
• W3207194677 title "MA06.05 Patterns of Care in Maintenance Therapy in U.S. Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NCSLC)" @default.
• W3207194677 doi "https://doi.org/10.1016/j.jtho.2021.08.137" @default.
• W3207194677 hasPublicationYear "2021" @default.
• W3207194677 type Work @default.
• W3207194677 sameAs 3207194677 @default.
• W3207194677 citedByCount "0" @default.
• W3207194677 crossrefType "journal-article" @default.
• W3207194677 hasAuthorship W3207194677A5018209224 @default.
• W3207194677 hasAuthorship W3207194677A5018712784 @default.
• W3207194677 hasAuthorship W3207194677A5025327083 @default.
• W3207194677 hasAuthorship W3207194677A5063005747 @default.
• W3207194677 hasAuthorship W3207194677A5068203031 @default.
• W3207194677 hasAuthorship W3207194677A5078183404 @default.
• W3207194677 hasAuthorship W3207194677A5089989046 @default.
• W3207194677 hasBestOaLocation W32071946771 @default.
• W3207194677 hasConcept C121608353 @default.
• W3207194677 hasConcept C126322002 @default.
• W3207194677 hasConcept C143998085 @default.
• W3207194677 hasConcept C146357865 @default.
• W3207194677 hasConcept C151730666 @default.
• W3207194677 hasConcept C2776256026 @default.
• W3207194677 hasConcept C2777701055 @default.
• W3207194677 hasConcept C2777742743 @default.
• W3207194677 hasConcept C2780057760 @default.
• W3207194677 hasConcept C71924100 @default.
• W3207194677 hasConcept C86803240 @default.
• W3207194677 hasConceptScore W3207194677C121608353 @default.
• W3207194677 hasConceptScore W3207194677C126322002 @default.
• W3207194677 hasConceptScore W3207194677C143998085 @default.
• W3207194677 hasConceptScore W3207194677C146357865 @default.
• W3207194677 hasConceptScore W3207194677C151730666 @default.
• W3207194677 hasConceptScore W3207194677C2776256026 @default.
• W3207194677 hasConceptScore W3207194677C2777701055 @default.
• W3207194677 hasConceptScore W3207194677C2777742743 @default.
• W3207194677 hasConceptScore W3207194677C2780057760 @default.
• W3207194677 hasConceptScore W3207194677C71924100 @default.
• W3207194677 hasConceptScore W3207194677C86803240 @default.
• W3207194677 hasIssue "10" @default.
• W3207194677 hasLocation W32071946771 @default.
• W3207194677 hasOpenAccess W3207194677 @default.
• W3207194677 hasPrimaryLocation W32071946771 @default.
• W3207194677 hasRelatedWork W1967103478 @default.
• W3207194677 hasRelatedWork W2032912323 @default.
• W3207194677 hasRelatedWork W2148097028 @default.
• W3207194677 hasRelatedWork W2356105190 @default.
• W3207194677 hasRelatedWork W2372561159 @default.
• W3207194677 hasRelatedWork W2375344515 @default.
• W3207194677 hasRelatedWork W2380382254 @default.
• W3207194677 hasRelatedWork W2390152934 @default.
• W3207194677 hasRelatedWork W2412727163 @default.
• W3207194677 hasRelatedWork W4366525560 @default.
• W3207194677 hasVolume "16" @default.
• W3207194677 isParatext "false" @default.
• W3207194677 isRetracted "false" @default.
• W3207194677 magId "3207194677" @default.
• W3207194677 workType "article" @default.